KR20240041381A - Composition for the prevention or treatment of periodontal disease - Google Patents

Abstract

The present invention relates to a composition for preventing or treating periodontal disease, and more specifically, to relieve inflammation and promote alveolar bone formation by suppressing various oral bacteria that cause periodontitis using SDF1δ-derived peptide S10, which consists of the amino acid sequence of SEQ ID NO: 1. Provided is a composition for preventing or treating periodontal disease that has an activating effect.

Description

Composition for the prevention or treatment of periodontal disease}

The present invention relates to a composition for preventing or treating periodontal disease, and more specifically, to preventing or treating periodontal disease, which has the effect of alleviating inflammation and activating alveolar bone formation by suppressing various bacteria that cause periodontitis using SDF1δ-derived peptide S10. It relates to a composition for use.

Structurally, teeth are the hardest hard tissue in the human body and are supported by alveolar bone. The alveolar bone is firmly attached to the basal bone of the jaw bone, and the 2-3 mm part immediately adjacent to the tooth root is sometimes called periodontal bone. However, the term alveolar bone usually refers to all hard tissues including the periodontal bone. As the age increases, the alveolar bone gradually decreases, exposing the tooth roots. Additionally, when teeth are lost, alveolar bone is gradually lost. This intraoral alveolar bone attaches and supports the teeth by a layer of undifferentiated mesenchymal cells called the periodontal ligament, which is about 0.2 mm thick on average, and also distributes force to the alveolar bone so that the teeth can act as a cushion when chewing food. In addition, the sensation of teeth is transmitted to the alveolar bone through the periodontal ligament. In addition, the periodontal ligament is a layer in which undifferentiated mesenchymal cells exist and is structured to adapt to pressure while continuing bone remodeling without losing the structure and function of the entire fiber. Undifferentiated mesenchymal cells within the periodontal ligament move to adjacent tissues. They move toward the alveolar bone and are responsible for alveolar bone remodeling. On the other hand, they move toward the teeth and produce collagen fibers, which are continuously remodeled to hold the teeth more tightly. In these teeth, bone formation by osteoblasts and bone resorption by osteoclasts occur together in the alveolar bone, maintaining balance through continuous remodeling.

Periodontal disease is a disease that affects the gingiva and pubic bone that support the teeth and includes gingivitis and periodontitis. Gingivitis is an early periodontal disease in which the soft tissue of the gums becomes inflamed. The symptoms are relatively mild and recovery is reversible. Periodontitis is when gingivitis is not treated and the inflammation progresses to the gums and around the pubic bone. When the chronic inflammatory response stimulated by bacterial toxins progresses, the gums and teeth become separated and an infected periodontal pocket is formed, and periodontitis can become severe. As the periodontal pockets become deeper, the periodontal ligament becomes inflamed and bone loss occurs. In addition, when the metabolism of bone formation by osteoblasts and bone resorption by osteoclasts in the alveolar bone decreases below the limit due to various factors, alveolar bone formation disorders such as alveolar osteoporosis occur.

Treatment of periodontal disease has been used to establish the patient's improved oral hygiene, non-surgical or surgical calculus removal, root planing, gingival curettage, and periodontal tissue regeneration using new attachment. However, these surgical treatment methods are cumbersome and difficult to treat effectively, and are limited to treatment when the disease has progressed to a certain degree rather than prevention of the disease. Therefore, if not treated, most cases progress to chronic disease.

In addition, systemic antibiotics and topical sustained-release agents have been used as additional treatments, but too much medication is delivered to unnecessary areas, resulting in side effects, and there are examples of periodontal disease bacteria that have recently been isolated that show resistance to recently used antibiotics. It has been reported that it poses a serious problem.

In addition, periodontal disease, unlike general inflammation and arthritis, is characterized by complex causes such as loss of alveolar bone, inflammation, and periodontitis bacteria such as gingivalis, and has antibacterial and anti-inflammatory properties, promotion of osteoblasts into osteocytes, etc. Complex treatment methods are needed, but no drugs or treatments have been developed for such treatment.

Therefore, in order to supplement the above-mentioned problems, the present inventors recognized that it is urgent to develop a drug or therapeutic agent that can effectively treat periodontal disease, and completed the present invention.

Republic of Korea Patent No. 10-1759828 (announced on July 20, 2017)

The purpose of the present invention is to provide a composition for preventing and treating periodontal disease that has the effect of alleviating inflammation and activating alveolar bone formation by suppressing various bacteria that cause periodontal disease using SDF1δ-derived peptide S10.

Another object of the present invention is to provide an oral composition for preventing or improving periodontal disease that has the effect of alleviating inflammation and activating alveolar bone formation by suppressing various bacteria that cause periodontal disease using SDF1δ-derived peptide S10.

Another object of the present invention is to provide a composition for oral external application for preventing or improving periodontal disease, which has the effect of alleviating inflammation and activating alveolar bone formation by suppressing various bacteria that cause periodontal disease using SDF1δ-derived peptide S10. will be.

Another object of the present invention is to provide a health functional food for preventing or improving periodontal disease that has the effect of alleviating inflammation and activating alveolar bone formation by suppressing various bacteria that cause periodontal disease using SDF1δ-derived peptide S10.

The technical problems to be achieved by the invention are not limited to the technical problems mentioned above, and other technical problems not mentioned can be clearly understood by those skilled in the art from the description of the present invention.

In order to achieve the above object, the present invention provides a composition for preventing or treating periodontal disease and its use.

Hereinafter, this specification will be described in more detail.

The present invention provides a pharmaceutical composition for preventing or treating periodontal disease, comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

In the present invention, the periodontal disease may be one or more types selected from the group consisting of gingivitis, periodontitis, alveolar bone breakage, and alveolar bone osteodystrophy.

In the present invention, the alveolar bone dysplasia may be one or more types selected from the group consisting of alveolar bone osteoporosis, alveolar bone osteomalacia, and alveolar bone osteopenia.

In the present invention, the peptide is Porphyromonas gingivalis , Aggregatibacter actinomycetemcomitans , Fusobacterium nucleatum , and Streptococcus mu. The expression of one or more selected from the group consisting of Streptococcus mutans and Treponema denticola can be suppressed.

In addition, the present invention provides an oral composition for preventing or improving periodontal disease, comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

In addition, the present invention provides a composition for oral external application for preventing or improving periodontal disease, comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

In addition, the present invention provides a health functional food for preventing or improving periodontal disease, comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

All matters mentioned in the above pharmaceutical compositions, oral compositions, external oral compositions, and health functional foods for the prevention or treatment of periodontal disease apply equally unless contradictory.

The pharmaceutical composition, oral composition, oral external preparation composition, and health functional food for the prevention or treatment of periodontal disease of the present invention include Porphyromonas gingivalis , which causes periodontitis, using SDF1δ-derived peptide S10. It has the effect of alleviating inflammation and activating alveolar bone formation by suppressing various bacteria.

The effects of the present invention are not limited to the effects mentioned above, and other effects not mentioned will be clearly understood by those skilled in the art from the description of the claims.

Figure 1 shows the sequence of the stromal cell-derived factor 1 isoform delta precursor [Homo sapiens] from which the sequence of S10 is derived according to an embodiment of the present invention.
Figure 2 is a graph and image confirming the anti-inflammatory effect of S10 in THP-1 derived macrophages infected with Porphyromonas gingivalis (Pg), the causative agent of periodontal disease, according to an experimental example of the present invention. (a) shows cytokine production, (b) shows TLR signaling molecules, and (c) and (d) show changes in expression of MAPKs and NF-κB.
Figure 3 shows the inhibitory effect of S10 on inflammatory complex (inflammasome) activation in THP-1 derived macrophages infected with Porphyromonas gingivalis (Pg), the causative agent of periodontal disease, according to an experimental example of the present invention, ( A) to (c) show changes in expression of inflammatory complex-related factors, and (d) and (e) show the autophagy activation effect confirmed by real-time PCR and Western blot, respectively.
Figure 4 shows the effects of S10 on ER stress inhibition and reactive oxygen species inhibition in THP-1 derived macrophages infected with Porphyromonas gingivalis (Pg), the causative agent of periodontal disease, according to an experimental example of the present invention. This was confirmed, (a) is the result of real-time PCR, (b) is the Western blot result, and (c) shows changes in mitochondrial reactive oxygen species and (d) ER-mediated reactive oxygen species.
Figure 5 is a graph and image confirming the bone destruction inhibition effect of MC3T3-E1 cells, known as osteogenic cells, infected with Porphyromonas gingivalis, the causative agent of periodontal disease, according to an experimental example according to the present invention.
Figure 6 confirms the effect of S10 on alveolar bone loss caused by Porphyromonas gingivalis according to an experimental example according to the present invention, (a) is a bar graph showing the exposed bone surface area, and (b) is a bar graph showing the exposed bone surface area. The degree of alveolar bone loss was measured using micro-CT, and the area between the cementum-enamel junction of the three molars and the alveolar bone ridge was calculated using ImageJ.
Figure 7 is a graph confirming the anti-inflammatory effect of various bacteria causing periodontal disease according to an experimental example of the present invention, where Pg is Porphyromonas gingivalis and Aa is Aggregatibacter actinomycetes. Macrophages infected with Aggregatibacter actinomycetemcomitans , Fn is Fusobacterium nucleatum , Sm is Streptococcus mutans , and Td is Treponema denticola . means.

The terms used in this specification are general terms that are currently widely used as much as possible while considering the function in the present invention, but this may vary depending on the intention or precedent of a person skilled in the art, the emergence of new technology, etc. In addition, in certain cases, there are terms arbitrarily selected by the applicant, and in this case, the meaning will be described in detail in the description of the relevant invention. Therefore, the terms used in the present invention should be defined based on the meaning of the term and the overall content of the present invention, rather than simply the name of the term.

Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by a person of ordinary skill in the technical field to which the present invention pertains. Terms defined in commonly used dictionaries should be interpreted as having a meaning consistent with the meaning in the context of the related technology, and unless clearly defined in the present application, should not be interpreted in an ideal or excessively formal sense. No.

The numerical range includes the values defined in the range above. Every maximum numerical limit given throughout this specification includes all lower numerical limits as if the lower numerical limit were explicitly written out. Every minimum numerical limit given throughout this specification includes every higher numerical limit as if such higher numerical limit was clearly written. All numerical limits given throughout this specification will include all better numerical ranges within the broader numerical range, as if the narrower numerical limits were clearly written.

Hereinafter, examples of the present invention will be described in detail, but it is obvious that the present invention is not limited to the following examples.

Pharmaceutical composition for preventing or treating periodontal disease

The present invention provides a pharmaceutical composition for preventing or treating periodontal disease, comprising SDF1δ-derived peptide S10 as an active ingredient.

The SDF1δ-derived peptide S10 may consist of the amino acid sequence of SEQ ID NO: 1 below.

SEQ ID NO: 1: ISAAPAGKRV IAGAR

The periodontal disease refers to a disease of gum bones and adjacent tissues. Periodontal disease begins with bacterial infection, and as the inflammatory reaction progresses due to bacterial toxins, periodontal pockets are formed between the gums and teeth. As the disease worsens, the depth of the periodontal pockets deepens, and inflammation spreads to the periodontal ligament and bone. Disappearance occurs. Alternatively, when the balance between bone formation and bone resorption in the alveolar bone is broken, bone resorption exceeds bone formation, and bone mass decreases below the limit, alveolar bone dysplasia, a type of periodontal disease, occurs.

More specifically, the periodontal disease may be one or more types selected from the group consisting of gingivitis, periodontitis, alveolar bone breakage, and alveolar bone osteodystrophy.

The periodontal disease is caused by Porphyromonas gingivalis , Aggregatibacter actinomycetemcomitans , Fusobacterium nucleatum , and Streptococcus mutans. ), and Treponema denticola . It may be a disease caused by one or more bacteria selected from the group consisting of, but is not limited to this.

The above bacteria are a bacterial species mainly found in oral pulp infections, and various periodontal disease symptoms such as cavities, periodontitis, and bad breath may appear in the oral cavity where these strains overproliferate.

In addition, the alveolar bone dysplasia may be one or more types selected from the group consisting of alveolar bone osteoporosis, alveolar bone osteomalacia, and alveolar bone osteopenia.

The SDF1δ-derived peptide S10 is Porphyromonas gingivalis , Aggregatibacter actinomycetemcomitans , Fusobacterium nucleatum , and Streptococcus mutans ( Streptococcus mutans ), and Treponema denticola ( Treponema denticola ) can suppress the expression of one or more selected from the group consisting of.

More specifically, the SDF1δ-derived peptide S10 has anti-inflammatory effects on periodontal diseases caused by Porphyromonas gingivalis, the causative bacteria of periodontitis, such as THP-1-derived macrophages, cytokine production, TLR signaling molecules, MAPKs and NF-κB. It may have an expression inhibition effect, etc. In addition, the SDF1δ-derived peptide S10 has an inhibitory effect on bone destruction and increases the expression of osteogenic factors such as RUNX2, BMP-2/4, and OSX in MC3T3-E1 cells (osteogenic cells) infected with Porphyromonas gingivalis, the causative agent of periodontitis. It can have an effect.

The pharmaceutical composition contains the SDF1δ-derived peptide S10 as an active ingredient, may include a pharmaceutically acceptable carrier, and can be formulated into powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols according to conventional methods. It can be formulated in the form of oral dosage forms, topical preparations, and sterile injectable solutions. The pharmaceutically acceptable carriers include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline. It may include cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.

Additionally, the pharmaceutical composition of the present invention may contain diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Oral solid preparations include tablets, pills, powders, granules, capsules, etc. These solid preparations contain at least one excipient, such as starch, calcium carbonate, sucrose, or lactose. ), gelatin, etc., and may include lubricants such as magnesium stearate and talc. Oral liquid preparations include suspensions, oral solutions, emulsions, syrups, etc., and may contain diluents such as water and liquid paraffin, humectants, sweeteners, fragrances, and preservatives. Parenteral preparations include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, and freeze-dried preparations. Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and ethyl oleate. It may include injectable esters such as .

The pharmaceutical composition of the present invention can be administered via conventional routes: intravenous, intraarterial, intraperitoneal, intramuscular, intraarterial, intraperitoneal, intrasternal, transdermal, intranasal, inhalational, topical, rectal, oral, intraocular or intradermal. It can be administered in any way. Preferably, the pharmaceutical composition of the present invention can be administered orally or subcutaneously, but the route of administration is not limited thereto.

In the pharmaceutical composition of the present invention, the dosage of the active ingredient varies depending on the patient's condition and weight, degree of disease, drug type, administration route and period, but may be appropriately selected depending on the case. For example, the SDF1δ-derived peptide S10 can be administered at a dose of 0.0001 to 500 mg/kg per day, preferably 0.01 to 300 mg/kg, and may be administered once a day or in divided doses. .

Oral composition for preventing or improving periodontal disease

The present invention provides an oral composition for preventing or improving periodontal disease, comprising peptide S10 derived from SDF1δ consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

Corresponding features may be substituted for the parts described above.

The term “oral composition” used in the present invention refers to a composition administered orally that has the effect of inhibiting the differentiation of osteoclasts and reducing the adjustment distance for cementum and gum tissue recovery values.

In the oral composition, the formulation may be, for example, a film, toothpaste, mouthwash, ointment, spray, dressing solution, liniment, dental floss, or periodontal bag.

The oral composition contains the SDF1δ-derived peptide S10 as an active ingredient, and may also contain wetting agents, foaming agents, preservatives, sweeteners, thickeners, water-soluble polymers, fragrances, and other ingredients. The additive according to the present invention is preferably contained in an amount of 0.1 to 90 parts by weight based on 100 parts by weight of the SDF1δ-derived peptide S10, but is not limited thereto.

The humectant is an ingredient for suppressing evaporation of water in the oral composition, and can be used by mixing one or more types selected from the group consisting of polyhydric alcohols such as glycerin, sorbitol solution, non-consolidated sorbitol solution, polyethylene glycol, and propylene glycol.

The foaming agent is an ingredient that has an emulsifying or solubilizing effect between the water-soluble and oil-soluble components in the composition and has a cleaning effect in the oral cavity, including sodium lauryl sulfate, sodium N-lauroyl sarcosylate, N-long-chain acyl glutamate, One or more types selected from the group consisting of anionic and nonionic surfactants such as sucrose fatty acid ester, polyoxyethylene hydrogenated castor oil, sorbitan fatty acid ester, and polyoxyethylene polyoxypropylene copolymer can be used in combination.

The preservative is an ingredient to extend the storage period and may include methyl paraoxybenzoate, benzoic acid, sodium benzoate, etc.

The sweetener and/or flavoring agent is an ingredient to improve the taste and refresh the aftertaste when using the product. Sweeteners include sodium saccharin, aspartame, stevioside, and licorice acid, and flavoring agents include peppermint, spearmint oil, Menthol, carvone, anethole, eugenol, etc. can be mixed and used.

The thickener is an ingredient that prevents phase separation over time by combining the water-insoluble inorganic powder component and the liquid component in the composition and adds viscosity to the composition, including carboxymethyl cellulose (CMC), carrageenan, sodium alkylate, and arabic. One or more types selected from the group consisting of rubber, xanthan gum, and other gums can be mixed and used.

The water-soluble polymer is hydroxypropyl cellulose-Klucel TM, hydroxypropyl methylcellulose, hydroxy ethylcellulose, ethylcellulose, carboxymethylcellulose, and dextran. (Dextran), gaur-gum, PVP (polyvinyl pyrrolidone), pectins, starches, gelatin, casein, sodium alginate, polyethlyene glycol ), and polyvinyl glycol, etc. can be used in combination with one or more selected from the group consisting of.

As the other additives, stabilizers such as sodium citrate for pH adjustment, fluorine agents with a cavity-inhibiting function, astringents such as zinc chloride, and food coloring such as Blue No. 1 can be used.

Oral topical composition for preventing or improving periodontal disease

The present invention provides an oral topical composition for preventing or improving periodontal disease, comprising SDF1δ-derived peptide S10 having the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

Corresponding features may be substituted for the parts described above.

The oral external preparation is not particularly limited thereto, but is preferably prepared and used in the form of ointment, lotion, spray, patch, cream, powder, suspension, gel or gel. Preferably, it can be formulated as a film, toothpaste, oral rinse solution, ointment, spray, dressing solution, liniment, dental floss, or periodontal bag. When using the oral external preparation of the present invention, solubilizers, thickeners and gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or non-ionic are added. Any other ingredients commonly used in oral external preparations, such as emulsifiers, fillers, sequestering agents and chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, etc. May contain commonly used auxiliaries.

Health functional food for preventing or improving periodontal disease

The present invention provides a health functional food for preventing or improving periodontal disease, comprising SDF1δ-derived peptide S10 consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

Corresponding features may be substituted for the parts described above.

The term "health functional food" used in the present invention refers to food manufactured and processed using raw materials or ingredients with functionality useful to the human body in accordance with Act No. 6727 on Health Functional Food, and "functional" refers to food. This means taking it for the purpose of controlling nutrients for the structure and function of the human body or obtaining useful effects for health purposes such as physiological effects.

The health functional food is manufactured according to a conventional method, and can be dried with a carrier and then encapsulated or formulated into other forms such as tablets, granules, powder, beverages, porridge, etc. In addition to those listed above, it can be manufactured in all food forms. do.

The health functional food of the present invention may contain common food additives, and its suitability as a “food additive” is determined in accordance with the general provisions of the Food Additive Code and General Test Methods approved by the Food and Drug Safety Administration, unless otherwise specified. It is determined in accordance with the relevant standards and standards.

Items listed in the "Food Additives Code" include, for example, chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid, natural additives such as reduced color, licorice extract, crystalline cellulose, high-lyan pigment, and guar gum, L -Combined preparations include sodium glutamate preparations, noodle additive alkaline preparations, preservative preparations, and tar coloring preparations.

The health functional food of the present invention can be used in a variety of foods and beverages, for example, various foods, beverages, gum, tea, vitamin complexes, health functional supplements, food additives, etc., and can be used in powders, granules, tablets, etc. It can be used in capsule, pill or beverage form. In addition to those described above, it may be in any food form.

The advantages and features of the present invention and methods for achieving them will become clear with reference to the embodiments described in detail below. However, the present invention is not limited to the embodiments disclosed below and may be implemented in various different forms, and only the embodiments are provided to ensure that the disclosure of the present invention is complete, and are provided by those skilled in the art It is provided to fully inform those who have the scope of the invention, and the present invention is only defined by the scope of the claims.

<Example 1> SDF1δ-derived peptide S10

The sequence of S10 was taken from the stromal cell-derived factor 1 isoform delta precursor [Homo sapiens] (Accession: NP_001171605.1) (Figure 1). After testing with SDF1-derived peptide samples, recombinant proteins of the selected sequences were synthesized at Peptrotech (S10).

SDF1P-10 (s10): ISAAPAGKRV IAGAR

<Experimental Example 1> Porphyromonas gingivalis ( Porphyromonas gingivalis ) confirmed anti-inflammatory effect in THP-1 derived macrophages infected with

It was confirmed whether the SDF1δ-derived peptide S10 synthesized according to Example 1 had an anti-inflammatory effect in THP-1-derived macrophages infected with Porphyromonas gingivalis, the causative agent of periodontal disease.

First, Porphyromonas gingivalis (strain 33277) contains 5 mg/mL hemin and 0.5 mg/mL 3-phytyl-menadione (vitamin K) at 37°C. Anaerobic culture was performed in Gifu anaerobic medium broth containing (80% nitrogen, 10% hydrogen and 10% CO ₂ ). Bacteria were washed and resuspended in RPMI medium to infect THP-1 cells at a multiplicity of infection (MOI) of 50. Afterwards, the SDF1δ-derived peptide S10 was instilled into THP-1-derived macrophages infected with Porphyromonas gingivalis (Pg).

As a result, referring to Figure 2, SDF1δ-derived peptide S10 produced in Example 1 reduced cytokine production in THP-1-derived macrophages infected with Porphyromonas gingivalis (Pg) (a), TLR It was shown to inhibit the expression of signaling molecules (b), MAPKs and NF-κB (c, d).

In addition, referring to Figure 3, the activation of the inflammatory complex (inflammasome) of THP-1 derived macrophages infected with Porphyromonas gingivalis (Pg) is inhibited by the SDF1δ-derived peptide S10 produced in Example 1. It was found that

In other words, it can be confirmed that the SDF1δ-derived peptide S10 has an anti-inflammatory effect.

<Experimental Example 2> Porphyromonas gingivalis ( Porphyromonas gingivalis ) Confirmed the effect of suppressing ER stress and suppressing reactive oxygen species in THP-1-derived macrophages infected with

After confirming through RNA seq that the factors of endoplasmic reticulum stress (ER stres) increase according to the degree of periodontitis in periodontitis patients, the SDF1δ-derived peptide S10 synthesized according to Example 1 was identified as Porphyromonas gingivalis, the causative agent of periodontal disease. The effects of suppressing ER stress and reactive oxygen species in infected THP-1-derived macrophages were confirmed through real-time PCR and western blot.

As a result, as shown in Figure 4, it was confirmed that ER stress expression and mitochondrial ROS, which increased in THP-1-derived macrophages infected with Porphyromonas gingivalis, were suppressed by SDF1δ-derived peptide S10 prepared in Example 1. You can.

<Experimental Example 3> Porphyromonas gingivalis ( Porphyromonas gingivalis ) confirmed the inhibitory effect on bone destruction in MC3T3-E1 cells (osteogenic cells) infected with

In order to confirm the effect of the SDF1δ-derived peptide S10 synthesized according to Example 1 on suppressing bone destruction in MC3T3-E1 cells, known as osteogenic cells infected with Porphyromonas gingivalis, the causative agent of periodontal disease, S10 was mixed with Porphyromonas gingivalis. It was spotted on MC3T3-E1 cells (osteogenic cells) infected with gingivalis.

As a result, referring to Figure 5, in MC3T3-E1 cells (osteogenic cells) infected with Porphyromonas gingivalis by SDF1δ-derived peptide S10 prepared in Example 1, the osteogenic factors RUNX2 and BMP-2/4 and OSX expression can be confirmed to increase.

In addition, the alveolar bone loss caused by Porphyromonas gingivalis oral infection was measured using micro-CT and compared with the normal control group. Referring to Figure 6, the S10 showed alveolar bone loss caused by Porphyromonas gingivalis. It can be confirmed that the symptoms of experimental periodontitis are improved by suppressing it.

<Experimental Example 4> Confirmation of anti-inflammatory effect in THP-1 derived macrophages infected with various bacteria

The SDF1δ-derived peptide S10 synthesized according to Example 1 is a bacterium related to periodontal disease, Aggregatibacter actinomycetemcomitans (Aa), Fusobacterium nucleatum (Fn), It was confirmed whether THP-1 derived macrophages infected with Streptococcus mutans (Sm) and Treponema denticola (Td) have an anti-inflammatory effect. The detailed experimental method is the same as Experimental Example 1 above.

As a result, as shown in Figure 7, it can be seen that when macrophages infected with the above bacteria were treated with SDF1δ-derived peptide S10, the TNF-α value was significantly reduced.

From the above description, those skilled in the art to which the present invention pertains will understand that the present invention can be implemented in other specific forms without changing its technical idea or essential features. In this regard, the embodiments described above should be understood in all respects as illustrative and not restrictive.

Claims (7)

A pharmaceutical composition for preventing or treating periodontal disease, comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.
According to claim 1,
The periodontal disease is,
A pharmaceutical composition for the prevention or treatment of periodontal disease, characterized in that it is one or more selected from the group consisting of gingivitis, periodontal inflammation, alveolar bone breakage, and alveolar bone osteodystrophy. .
According to claim 2,
The alveolar bone dysplasia is
A pharmaceutical composition for the prevention or treatment of periodontal disease, characterized in that it is one or more selected from the group consisting of alveolar bone osteoporosis, alveolar bone osteomalacia, and alveolar bone osteopenia.
According to claim 1,
The peptide is,
Porphyromonas gingivalis , Aggregatibacter actinomycetemcomitans , Fusobacterium nucleatum , Streptococcus mutans , and Tre A pharmaceutical composition for preventing or treating periodontal disease, characterized in that it inhibits the expression of one or more selected from the group consisting of Treponema denticola .
An oral composition for preventing or improving periodontal disease, comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.
A composition for oral external application for preventing or improving periodontal disease, comprising as an active ingredient a peptide consisting of the amino acid sequence of SEQ ID NO: 1.
A health functional food for preventing or improving periodontal disease, comprising as an active ingredient a peptide consisting of the amino acid sequence of SEQ ID NO: 1.